Skip to main content

news

Freshfields Bruckhaus Deringer, Gibson, Dunn & Crutcher, King & Wood Mallesons and DLA Piper have advised Chinese biopharma company Hutchmed on its HK$4.17 billion ($537 million) secondary listing in Hong Kong.

Linklaters, Davis Polk & Wardwell and JunHe are counselling the joint sponsors and underwriters, namely Morgan Stanley Asia, Jefferies Hong Kong and China International Capital Corporation.

Listed on the AIM market of the London Stock Exchange since 2006, Hutchmed also has American Depositary Shares (ADSs) listed on the Nasdaq Global Select Market. It is a biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases.

Partners Kevin Cheung and Christopher Yip led the Linklaters team. Conyers is providing offshore legal advice to the issuer.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, SAM, Sidley advise on Torrent Power’s $413 mln QIP

by Nimitt Dixit |

Indian law firm Khaitan & Co has advised Torrent Power on its equity offering of $413 million through a qualified institutional placement of shares. Shardul Amarchand Mangaldas & Co and Sidley Austin advised the bookrunning lead managers on the deal.

Deals

IndusLaw guides Zepto’s $350 mln funding round

by Nimitt Dixit |

IndusLaw has guided Indian quick commerce company Zepto on its latest $350 million funding round led by Motilal Oswal's Private Wealth division.

Deals

9 firms advise on milestone $8.2 bln cross-border insurance deal

by Sarah Wong |

Global law firms Debevoise & Plimpton, Kirkland & Ellis and Herbert Smith Freehills are acting for Bermuda-based insurer Resolution Life on its $8.2 billion sale to Japan’s Nippon Life Insurance, the largest overseas acquisition by a Japanese insurer to date.